Telix Pharmaceuticals Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TLX Nasdaq 2830 telixpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Telix Pharmaceuticals Limited

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions - Jun 22nd, 2026 3:40 pm
Telix Pharmaceuticals (TLX), United Imaging Healthcare Form Strategic Theranostics Research Partnership - Jun 17th, 2026 1:38 pm
ASX Growth Companies With Insider Ownership Up To 20% - Jun 4th, 2026 1:38 pm
Telix and United Imaging Announce Strategic Theranostics Collaboration - Jun 2nd, 2026 5:00 am
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 - Jun 1st, 2026 3:00 pm
Is Telix (ASX:TLX) Quietly Assembling a Connected Oncology Platform That Reshapes Its Moat? - May 28th, 2026 3:10 pm
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences - May 27th, 2026 5:00 am
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing - May 18th, 2026 3:00 pm
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - May 15th, 2026 4:30 am
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC - May 4th, 2026 3:00 pm
Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares - May 1st, 2026 2:50 pm
TLX101-Px (Pixlumi®) MAA Accepted in Europe - Apr 30th, 2026 6:48 pm
How TLX597-Tx Phase 2 Dosimetry Data Will Impact Telix Pharmaceuticals (ASX:TLX) Investors - Apr 30th, 2026 12:04 am
Telix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears End - Apr 29th, 2026 7:36 pm
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer - Apr 29th, 2026 3:00 pm
Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. - Apr 29th, 2026 2:43 pm
Telix Pharmaceuticals (TLX): How Are Its Clinical Programs Doing? - Apr 28th, 2026 11:30 am
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach - Apr 27th, 2026 5:44 pm
ASX Growth Leaders With High Insider Ownership April 2026 - Apr 26th, 2026 1:38 pm
Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ - Apr 23rd, 2026 5:30 am